Patrys has developed two humanised forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody, and which have been further optimised for efficacy and manufacturability. 

Patrys, and its’ commercial partners, are also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells.

Patrys is in the process of scaling up the manufacture of clinical grade PAT-DX1 with the first human clinical trial expected to commence in mid 2023.

Compound Discovery Preclinical Clinical


Patrys has a number of research collaborations in place including a major program with the Yale University. Patrys has an active program to establish new commercial and research partnerships in order to leverage the full potential of its deoxymab technology for the development of revolutionary, new therapeutic products.

Current Deoxymab Portfolio

PAT-DX1 antibody fragment

PAT-DX1 is a dimer of a small antibody fragment derived from a humanised version of the binding domain from the original mouse deoxymab antibody 3E10. Patrys is currently scaling up the production of clinical grade PAT-DX1 with a view to initiating first-in-man studies in 2024. PAT-DX1 is likely to have clinical utility for treating primary and secondary brain cancers due to its ability to cross the blood brain barrier. It also may have utility for treating cancers with existing DDR deficiencies, or in combination with other DNA damaging agents such as radiation and many chemotherapy drugs.

PAT-DX3 full sized antibody

PAT-DX3 is a humanised, full-sized antibody, that has been further optimised to improve its therapeutic potential. PAT-DX3 has the DNA-binding and DNA damage repair (DDR) blocking properties of PAT-DX1, but is expected to have different pharmaceutic properties (tissue distribution, pharmacokinetic profile etc) due to its larger size.  Patrys believes these will open up further opportunities to leverage its deoxymab platform and to develop additional therapeutic products.

PAT-DX1-NP conjugated to nanoparticles

Through both its own internal R&D programs and a growing number of partnerships, Patrys is using PAT-DX1 to develop new drugs based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells.